CompletedPhase 2NCT03221257
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Michael Roth
- Principal Investigator
- Michael D Roth, MDPulmonary & Critical Care Medicine, Geffen School of Medicine at UCLA
- Intervention
- Pirfenidone (PFD)(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (16)
- University of California Los Angeles, Los Angeles, California, United States
- University of Colorado, Aurora, Colorado, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Northwestern University, Chicago, Illinois, United States
- Indiana University Health, Indianapolis, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts, United States
- Boston University, School of Medicine, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Rutgers University, New Brunswick, New Jersey, United States
- Hospital for Special Surgery, New York, New York, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Texas Medical School at Houston, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
University of Michigan · Genentech, Inc. · University of California, Los Angeles
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03221257 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University